Fundamentals are weak (no revenue; losses widened YoY in 2025/Q3), so there’s no fundamental “floor” to confidently buy into.
With no clear catalyst/news flow and no supportive options/flow data provided, the risk/reward is unfavorable for an impatient buyer.
Technical Analysis
Trend: Bearish structure with moving averages stacked negatively (SMA_200 > SMA_20 > SMA_5), indicating the broader downtrend remains intact.
Momentum: MACD histogram at -0.0344 (below zero) and negatively contracting, suggesting bearish momentum persists (even if the rate of decline is moderating).
RSI: RSI_6 = 43.578 (neutral-to-weak), not showing an oversold bounce setup.
Key levels:
Pivot: 3.974 (price 3.7 is below pivot, bearish bias)
Support: S1 3.451 then S2 3.128 (breaks increase downside risk)
Resistance: R1 4.497 then R2 4.819 (needs reclaim to shift tone)
Pattern-based forward bias provided: ~40% chance of -0.2% next day; +3.69% next week; +3.3% next month—modest upside probabilities, but not strong enough to override the current downtrend and weak tape.
Positive Catalysts
and reclaims the pivot (3.974), which could open room toward 4.
Pattern study suggests modest upside potential over 1-week/1-month horizons (+3.69% / +3.3%), implying some rebound odds if support holds.
Neutral/Negative Catalysts
and MACD below zero reinforce a downtrend.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 0 (0.00% YoY) — no demonstrated top-line traction.
Net income: -1,595,959 (down -32.20% YoY) — losses widened versus prior year.
Gross margin: 0 (0.00% YoY) — consistent with no revenue generation.
Overall: financial trend does not support a “buy now” decision; the company is still in a loss-making phase without visible revenue growth in the snapshot.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided, so a recent trend in Wall Street upgrades/downgrades cannot be confirmed.
Wall Street-style pros (conceptual): optionality if commercialization/partnership milestones emerge; small-float names can move quickly on catalysts.
Wall Street-style cons (conceptual): lack of revenue, widening losses, and weak technical trend typically keep institutional/analyst enthusiasm limited and increase perceived dilution/financing risk.
Net: absent supportive analyst/target momentum, the balance of pros/cons leans negative right now.
Wall Street analysts forecast NDRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NDRA is 30 USD with a low forecast of 30 USD and a high forecast of 30 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast NDRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NDRA is 30 USD with a low forecast of 30 USD and a high forecast of 30 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
